Harbour BioMed 
Welcome,         Profile    Billing    Logout  
 0 Products   0 Diseases  0 Products   0 Trials   1 News 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tanfanercept (HL036) / Daewoong Pharma
ChiCTR2000039903: A Phase 3, Multicenter, Randomized, Double–Blinded and Placebo–Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects with Moderate and Severe Dry Eye

Recruiting
3
674
 
Local administration of HBM9036 (HL036) eye drops (0.25%) to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks ;Local administration of placebo to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks
Xiamen Eye Center Affiliated to Xiamen University; Harbour BioMed (Guangzhou) Co., Ltd., Fully self-funded
Dry Eye
 
 
NCT04633213: A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Recruiting
3
674
RoW
HBM9036 0.25% Ophthalmic Solution, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye
12/22
04/23
VELOS-4, NCT06400589: A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

Suspended
3
750
US
tanfanercept, Vehicle
HanAll BioPharma Co., Ltd.
Dry Eye
08/25
08/25
batoclimab (IMVT-1401) / Roivant
2021-000249-42: Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG Studio di fase 3 per valutare l’efficacia e la sicurezza di Batoclimab come terapia di induzione e di mantenimento in partecipanti adulti affetti da miastenia grave generalizzata (gMG).

Ongoing
3
240
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Diseases [C] - Nervous System Diseases [C10]
 
 
MG, NCT05039190: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized Patients

Completed
3
132
RoW
HBM9161 Injection (680mg), Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
01/23
01/23
2022-002787-68: Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Studio di fase 3 per testare Batoclimab in partecipanti affetti da oftalmopatia tiroidea (TED) attiva

Not yet recruiting
3
100
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences, GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Diseases [C] - Eye Diseases [C11]
 
 
NCT05332210: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Recruiting
3
144
RoW
HBM9161 Injection (680mg)
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
09/23
12/23
ChiCTR2100050903: Multicenter, randomized, double-blind, placebo-controlled, phase 2/3 operational seamless, group sequential design study of the efficacy and safety of HBM9161 subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia Gravis
 
 
NCT05403541 / 2021-000249-42: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Active, not recruiting
3
240
Europe, Canada, Japan, US, RoW
Batoclimab 680 mg SC weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis
03/25
04/25
ChiCTR2200059452: A long-term open-label extension study to evaluate the safety of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 680 mg was administered once a week (QW) ;HBM9161 340mg was administered 6 times per cycle for two cycles
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia gravis
 
 
NCT05517421 / 2022-002787-68: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Active, not recruiting
3
100
Europe, Canada, Japan, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05524571 / 2022-002788-30: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Recruiting
3
100
Europe, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05517447 / 2022-002839-66: Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Recruiting
3
180
Europe, US, RoW
Observational cohort study, Batoclimab, IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
08/26
08/26
NCT04428255: A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

Recruiting
2/3
36
RoW
HBM9161 Dose A, HBM9161 Dose B, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Primary Immune Thrombocytopenic Purpura
07/21
03/23
NCT05015127: A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

Recruiting
2/3
36
RoW
HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7
Harbour BioMed (Guangzhou) Co. Ltd.
Thyroid Ophthalmopathy
10/22
12/22
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients, ChiCTR2000033560: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Not yet recruiting
2
30
 
HBM9161 dose 1 ;HBM9161 dose 2 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Myasthenia Gravis
 
 
ChiCTR2100050401: A randomized, double-blind, placebo-controlled, phase 2/3 operational seamless design clinical study to evaluate the efficacy and safety of subcutaneous injection of HBM9161 in Chinese patients with active, moderate-to-severe thyroid eye disease (TED)

Not yet recruiting
2
30
 
HBM9161 Once a week ;HBM9161 1 time / week + 2 times / week ;Placebo
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Harbour BioMed(Suzhou) Co., Ltd., Harbour BioMed(Suzhou) Co., Ltd.
Thyroid Eye Disease (TED)
 
 
2022-002894-27: Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones.

Not yet recruiting
2
45
Europe
batoclimab, IMVT-1401, Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves, disease, An immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism)., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05907668 / 2022-002894-27: A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Active, not recruiting
2
35
Europe
IMVT-1401 (batoclimab), IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves Disease
07/25
07/25
NCT05581199 / 2022-002718-17: To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Active, not recruiting
2
277
Europe, Canada, US, RoW
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Placebo
Immunovant Sciences GmbH, Immunovant Sciences, GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
01/26
01/27
ChiCTR2000029151: Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of HBM9161 weekly subcutaneous administration in patients with neuromyelitis optica spectrum disorders (NMOSD) in China.

Recruiting
1
18
 
HBM9161
The Third Affiliated Hospital, Sun Yat-Sen Unvierity; Harbour BioMed (Guangzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Neuromyelitis optica spectrum disorders
 
 
tagitanlimab (HBM9167) / Harbour BioMed
NCT05294172: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
295
RoW
KL-A167, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin injection, Placebo
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma, Recurrent or Metastatic
12/27
12/27
OptiTROP-Lung01, NCT05351788: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Recruiting
2
110
RoW
SKB264, KL-A167, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-small Cell Lung Cancer
08/24
04/26
OptiTROP-Breast05, NCT05445908: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Recruiting
2
175
RoW
SKB264, KL-A167
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple-negative Breast Cancer and HR+/HER2- BC
04/25
07/25
ChiCTR1900023375: Phase Ib study to evaluate the safety, feasibility and efficacy of KL-A167 monotherapy in neoadjuvant/adjuvant therapy for resectable lung squamous cell carcinoma.

Not yet recruiting
1
30
 
KL-A167
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Most of the resources needed for the research project are self-raised by the sponsor, and the experimental drugs and some funds are sponsored by sichuan kelunbotai bio-pharmaceutical co., LTD
lung squamous cell carcinoma
 
 
porustobart (HBM4003) / Harbour BioMed
NCT04135261: A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Completed
1
65
RoW
HBM4003
Harbour BioMed US, Inc.
Advanced Solid Tumor
01/23
02/23
NCT04866485: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Not yet recruiting
1
66
NA
HBM4003 and pembrolizumab, HBM4003
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumor
02/23
02/23
NCT05167071: HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Active, not recruiting
1
53
RoW
HBM4003, Porustobart, Toripalimab, Tislelizumab
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumors, Neuroendocrine Tumors, CRC
09/25
06/26
NCT04727164: Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

Not yet recruiting
1
61
NA
HBM4003 and Triprilimab, HBM4003
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumors
11/23
11/23
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors

Not yet recruiting
1
67
NA
HBM4003 and Triprilimab
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumors
05/24
05/24
HBM1020 / Harbour BioMed
NCT05824663: A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Not yet recruiting
1
50
NA
HBM1020
Harbour BioMed US, Inc.
Advanced Solid Tumor
12/24
06/25
HBM7008 / Harbour BioMed
CLN-418-001, NCT05306444: CLN-418 Study on Subjects With Advanced Solid Tumors

Completed
1
48
US, RoW
CLN-418, HBM7008
Harbour BioMed US, Inc., Harbour BioMed US, Inc.
Advanced Solid Tumor
08/24
09/24
AZD5863 / AstraZeneca
D9750C00001, NCT06005493: Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
240
Europe, Japan, US, RoW
AZD5863
AstraZeneca
Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
12/26
12/26
WIN378 / Windward Bio
NCT05790694: A Trial of HBM9378 in Healthy Chinese Subjects

Recruiting
1
50
RoW
HBM9378 (SKB378) Injection, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Asthma
09/23
09/23
PF-08052666 / Pfizer
SGNMesoC2-001, NCT06466187: A Study of SGN-MesoC2 in Advanced Solid Tumors

Recruiting
1
365
Canada, US
PF-08052666, HBM9033; SGN-MesoC2
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
05/28
05/29
HBM7004 / Harbour BioMed
No trials found
HBM1047 / Harbour BioMed
No trials found
HBM1039 / Harbour BioMed
No trials found
HBM1053 / Harbour BioMed
No trials found
HBM7021 / Harbour BioMed
No trials found
HBM7024 / Harbour BioMed
No trials found
HBM7025 / Harbour BioMed
No trials found
HBM7023 / Harbour BioMed
No trials found
HBM1040 / Harbour BioMed
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tanfanercept (HL036) / Daewoong Pharma
ChiCTR2000039903: A Phase 3, Multicenter, Randomized, Double–Blinded and Placebo–Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects with Moderate and Severe Dry Eye

Recruiting
3
674
 
Local administration of HBM9036 (HL036) eye drops (0.25%) to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks ;Local administration of placebo to eyes, once in the morning and once in the evening, and the treatment lasts for 8 weeks
Xiamen Eye Center Affiliated to Xiamen University; Harbour BioMed (Guangzhou) Co., Ltd., Fully self-funded
Dry Eye
 
 
NCT04633213: A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Recruiting
3
674
RoW
HBM9036 0.25% Ophthalmic Solution, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye
12/22
04/23
VELOS-4, NCT06400589: A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

Suspended
3
750
US
tanfanercept, Vehicle
HanAll BioPharma Co., Ltd.
Dry Eye
08/25
08/25
batoclimab (IMVT-1401) / Roivant
2021-000249-42: Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG Studio di fase 3 per valutare l’efficacia e la sicurezza di Batoclimab come terapia di induzione e di mantenimento in partecipanti adulti affetti da miastenia grave generalizzata (gMG).

Ongoing
3
240
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Generalized Myasthenia Gravis (gMG) Miastenia grave generalizzata (gMG), Diseases [C] - Nervous System Diseases [C10]
 
 
MG, NCT05039190: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized Patients

Completed
3
132
RoW
HBM9161 Injection (680mg), Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
01/23
01/23
2022-002787-68: Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Studio di fase 3 per testare Batoclimab in partecipanti affetti da oftalmopatia tiroidea (TED) attiva

Not yet recruiting
3
100
Europe
Batoclimab, [IMVT-1401], Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences, GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Thyroid Eye Disease (TED) Oftalmopatia tiroidea (TED) attiva, Diseases [C] - Eye Diseases [C11]
 
 
NCT05332210: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Recruiting
3
144
RoW
HBM9161 Injection (680mg)
Harbour BioMed (Guangzhou) Co. Ltd.
Myasthenia Gravis
09/23
12/23
ChiCTR2100050903: Multicenter, randomized, double-blind, placebo-controlled, phase 2/3 operational seamless, group sequential design study of the efficacy and safety of HBM9161 subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia Gravis
 
 
NCT05403541 / 2021-000249-42: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Active, not recruiting
3
240
Europe, Canada, Japan, US, RoW
Batoclimab 680 mg SC weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Generalized Myasthenia Gravis
03/25
04/25
ChiCTR2200059452: A long-term open-label extension study to evaluate the safety of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis

Not yet recruiting
3
144
 
HBM9161 680 mg was administered once a week (QW) ;HBM9161 340mg was administered 6 times per cycle for two cycles
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd., self-funded
Myasthenia gravis
 
 
NCT05517421 / 2022-002787-68: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Active, not recruiting
3
100
Europe, Canada, Japan, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05524571 / 2022-002788-30: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Recruiting
3
100
Europe, US, RoW
Batoclimab, IMVT-1401, Placebo
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
12/25
12/25
NCT05517447 / 2022-002839-66: Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Recruiting
3
180
Europe, US, RoW
Observational cohort study, Batoclimab, IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Thyroid Eye Disease
08/26
08/26
NCT04428255: A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

Recruiting
2/3
36
RoW
HBM9161 Dose A, HBM9161 Dose B, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Primary Immune Thrombocytopenic Purpura
07/21
03/23
NCT05015127: A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

Recruiting
2/3
36
RoW
HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7
Harbour BioMed (Guangzhou) Co. Ltd.
Thyroid Ophthalmopathy
10/22
12/22
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients, ChiCTR2000033560: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Not yet recruiting
2
30
 
HBM9161 dose 1 ;HBM9161 dose 2 ;Placebo
Huashan Hospital Affiliated to Fudan University; Harbour BioMed (Suzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Myasthenia Gravis
 
 
ChiCTR2100050401: A randomized, double-blind, placebo-controlled, phase 2/3 operational seamless design clinical study to evaluate the efficacy and safety of subcutaneous injection of HBM9161 in Chinese patients with active, moderate-to-severe thyroid eye disease (TED)

Not yet recruiting
2
30
 
HBM9161 Once a week ;HBM9161 1 time / week + 2 times / week ;Placebo
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Harbour BioMed(Suzhou) Co., Ltd., Harbour BioMed(Suzhou) Co., Ltd.
Thyroid Eye Disease (TED)
 
 
2022-002894-27: Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones.

Not yet recruiting
2
45
Europe
batoclimab, IMVT-1401, Solution for injection in pre-filled syringe
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves, disease, An immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism)., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05907668 / 2022-002894-27: A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Active, not recruiting
2
35
Europe
IMVT-1401 (batoclimab), IMVT-1401
Immunovant Sciences GmbH, Immunovant Sciences GmbH
Graves Disease
07/25
07/25
NCT05581199 / 2022-002718-17: To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Active, not recruiting
2
277
Europe, Canada, US, RoW
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, IMVT-1401, Batoclimab 340 mg SC weekly, Placebo
Immunovant Sciences GmbH, Immunovant Sciences, GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
01/26
01/27
ChiCTR2000029151: Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of HBM9161 weekly subcutaneous administration in patients with neuromyelitis optica spectrum disorders (NMOSD) in China.

Recruiting
1
18
 
HBM9161
The Third Affiliated Hospital, Sun Yat-Sen Unvierity; Harbour BioMed (Guangzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd
Neuromyelitis optica spectrum disorders
 
 
tagitanlimab (HBM9167) / Harbour BioMed
NCT05294172: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
295
RoW
KL-A167, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin injection, Placebo
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma, Recurrent or Metastatic
12/27
12/27
OptiTROP-Lung01, NCT05351788: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Recruiting
2
110
RoW
SKB264, KL-A167, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-small Cell Lung Cancer
08/24
04/26
OptiTROP-Breast05, NCT05445908: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Recruiting
2
175
RoW
SKB264, KL-A167
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple-negative Breast Cancer and HR+/HER2- BC
04/25
07/25
ChiCTR1900023375: Phase Ib study to evaluate the safety, feasibility and efficacy of KL-A167 monotherapy in neoadjuvant/adjuvant therapy for resectable lung squamous cell carcinoma.

Not yet recruiting
1
30
 
KL-A167
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Most of the resources needed for the research project are self-raised by the sponsor, and the experimental drugs and some funds are sponsored by sichuan kelunbotai bio-pharmaceutical co., LTD
lung squamous cell carcinoma
 
 
porustobart (HBM4003) / Harbour BioMed
NCT04135261: A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Completed
1
65
RoW
HBM4003
Harbour BioMed US, Inc.
Advanced Solid Tumor
01/23
02/23
NCT04866485: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Not yet recruiting
1
66
NA
HBM4003 and pembrolizumab, HBM4003
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumor
02/23
02/23
NCT05167071: HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Active, not recruiting
1
53
RoW
HBM4003, Porustobart, Toripalimab, Tislelizumab
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumors, Neuroendocrine Tumors, CRC
09/25
06/26
NCT04727164: Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

Not yet recruiting
1
61
NA
HBM4003 and Triprilimab, HBM4003
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumors
11/23
11/23
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors

Not yet recruiting
1
67
NA
HBM4003 and Triprilimab
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumors
05/24
05/24
HBM1020 / Harbour BioMed
NCT05824663: A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Not yet recruiting
1
50
NA
HBM1020
Harbour BioMed US, Inc.
Advanced Solid Tumor
12/24
06/25
HBM7008 / Harbour BioMed
CLN-418-001, NCT05306444: CLN-418 Study on Subjects With Advanced Solid Tumors

Completed
1
48
US, RoW
CLN-418, HBM7008
Harbour BioMed US, Inc., Harbour BioMed US, Inc.
Advanced Solid Tumor
08/24
09/24
AZD5863 / AstraZeneca
D9750C00001, NCT06005493: Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
240
Europe, Japan, US, RoW
AZD5863
AstraZeneca
Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
12/26
12/26
WIN378 / Windward Bio
NCT05790694: A Trial of HBM9378 in Healthy Chinese Subjects

Recruiting
1
50
RoW
HBM9378 (SKB378) Injection, Placebo
Harbour BioMed (Guangzhou) Co. Ltd.
Asthma
09/23
09/23
PF-08052666 / Pfizer
SGNMesoC2-001, NCT06466187: A Study of SGN-MesoC2 in Advanced Solid Tumors

Recruiting
1
365
Canada, US
PF-08052666, HBM9033; SGN-MesoC2
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
05/28
05/29
HBM7004 / Harbour BioMed
No trials found
HBM1047 / Harbour BioMed
No trials found
HBM1039 / Harbour BioMed
No trials found
HBM1053 / Harbour BioMed
No trials found
HBM7021 / Harbour BioMed
No trials found
HBM7024 / Harbour BioMed
No trials found
HBM7025 / Harbour BioMed
No trials found
HBM7023 / Harbour BioMed
No trials found
HBM1040 / Harbour BioMed
No trials found

Download Options